Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma

Phase 1

Recruiting

• Conditions: B-cell Non-Hodgkin Lymphoma (B-NHL)
• Interventions: Biological: UCART20x22; Biological: CLLS52

• Registration Number: NCT05607420
• Lead Sponsor: Cellectis S.A.

Brief Summary

First-in-human, open-label, dose-finding and dose-expansion study of UCART20x22 administered intravenously in subjects with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). The purpose of this study is to evaluate the safety and clinical activity of UCART20x22 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D).

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-10-25
• Study First Submitted QC: 2022-10-31
• Study Start: 2022-11-01
• Study First Posted: 2022-11-07
• Status Verified: 2025-01
• Last Update Submitted: 2025-01-10
• Last Update Posted: 2025-01-13
• Primary Completion: 2027-11
• Study Completion: 2027-11

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Relapsed or refractory (R/R) mature B-NHL per 2016 WHO criteria and positive for CD20 and/or CD22
• Subjects with NHL subtypes defined by WHO:
• -Dose-Finding Part: R/R mature B-NHL (except chronic lymphocytic leukemia/small lymphocytic leukemia [CLL/SLL], Richter's transformation from prior CLL/SLL, Burkitt's lymphoma, and Waldenstrom's macroglobulinemia)
• -Dose-Expansion Part: R/R LBCL, defined as: i. DLBCL; ii. High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements; iii. Transformed FL or transformed marginal zone lymphoma (MZL); iv. Follicular lymphoma Grade 3B
• R/R disease after at least 2 lines of prior treatment, which must have included:
• -An Anti-CD20 MoAb and an anthracycline for DLBCL, high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, primary mediastinal large B-cell lymphoma (PMBCL), or transformed FL or MZL
• -An alkylating agent in combination with an anti-CD20 MoAb for FL
• -An anthracycline or bendamustine-containing chemotherapy regimen and a Bruton's tyrosine kinase (BTK) inhibitor for mantle cell lymphoma (MCL)
• -Autologous anti-CD19 CAR T-cell therapy, if approved and available for the indicated lymphoma subtype, unless the subject is unable or is ineligible to receive approved autologous anti-CD19 CAR T-cell therapy (e.g., fail leukapheresis or manufacture, unable to wait for manufacture, CD19 negative disease, etc.)
• Autologous hematopoietic stem cells must be available prior to the start of the LD regimen if the subject is considered high-risk for prolonged hematologic toxicity

Exclusion Criteria

• Prior use of an investigational product (except for cell or gene therapies and MoAbs) within 5 half-lives or within 14 days, whichever is shorter, prior to start of LD regimen
• Previous approved therapy including chemotherapy, biologic (except MoAbs), or targeted therapy for R/R B-NHL with 5 half-lives or within 14 days, whichever is shorter, prior to start of the LD regimen
• Prior MoAb therapy (approved or investigational) within 30 days prior to start of LD
• Prior systemic immunostimulatory agent within 3 half-lives prior to start of the LD regimen
• Prior cell or gene therapy (approved or investigational) within 6 weeks of the start of LD
• Prior cell or gene therapy (approved or investigational) targeting both CD20 and CD22
• Autologous HSCT infusion within 6 weeks of the start of LD
• Allogeneic HSCT within 3 months of the start of LD, or donor lymphocyte infusion within 6 weeks of the start of LD
• Active acute or chronic graft versus host disease (GvHD). Subjects should be off all immunosuppressive therapies for at least 6 weeks prior to start of LD
• Radiotherapy within 8 weeks (except for palliative radiotherapy for specific on-target lesions) (prior to start of LD regimen)
• Evidence of active central nervous system (CNS) lymphoma or previous CNS involvement of R/R B-NHL
• Presence of an active and clinically relevant CNS disorder
• Daily treatment with >20 mg prednisone or equivalent
• Known active infection, or reactivation of a latent infection, whether bacterial or viral, fungal, mycobacterial, or other pathogens
• History of hypersensitivity to alemtuzumab
• History of neutralizing anti-drug antibody against alemtuzumab
• Any known uncontrolled cardiovascular disease within 3 months of enrollment
• Subjects requiring immunosuppressive treatment
• Major surgery within 28 days prior to start of LD
• Evidence of another uncontrolled malignancy within 2 years prior to Screening (except in situ nonmelanoma skin cell cancers and/or carcinoma in-situ of the cervix)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Dose finding part	CLLS52	UCART20x22 tested at several dose levels until the Maximum Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RP2D) is identified. Dose expansion part: UCART20x22 administered at the RP2D determined during the dose finding part
Dose finding part	UCART20x22	UCART20x22 tested at several dose levels until the Maximum Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RP2D) is identified. Dose expansion part: UCART20x22 administered at the RP2D determined during the dose finding part

Primary Outcome Measures

Name	Time	Method
Dose finding and expansion parts: Incidence of adverse events/serious adverse events/dose limiting toxicity [Safety and Tolerability]	From study entry through month 12	Incidence, nature and severity of adverse events and serious adverse events in relation to UCART20x22 and/or lymphodepletion
Dose finding part: Occurrence of Dose Limiting Toxicities (DLTs)	Up to Day 28 post UCART20x22 infusion

Secondary Outcome Measures

Name	Time	Method
Investigator assessed overall response rate (ORR) according to Lugano Response Criteria for Malignant Lymphoma	At Day 28, Day 84, Month 6, Month 9, Month 12
Progression-free survival (PFS)	From the first day of any study treatment to the date of disease progression or death from any cause, whichever occurs first, assessed up to Month 12
Duration of Response	From achievement of the initial response to disease relapse/progression or death from any cause, assessed up to Month 12
Overall survival	From initiation of any study treatment to death from any cause, assessed up to Year 15

Trial Locations

Locations (10)

University of Chicago; 🇺🇸 Chicago, Illinois, United States

Massachusetts General Hospital; 🇺🇸 Boston, Massachusetts, United States

Rutgers Cancer Institute of New Jersey; 🇺🇸 New Brunswick, New Jersey, United States

Sarah Cannon - St. David South Austin Medical Center; 🇺🇸 Austin, Texas, United States

Hôpital Lyon Sud; 🇫🇷 Pierre-Bénite, Auvergne Rhone Alpe, France

Hôpital Saint Louis; 🇫🇷 Paris, Ile de France, France

CHU de Nantes; 🇫🇷 Alexis-Ricordeau, Nantes, France

CHU de Montpellier; 🇫🇷 Montpellier, Occitanie, France

Clínica Universidad de Navarra; 🇪🇸 Pamplona, Navarra, Spain

Hospital Universitario Virgen del Rocío; 🇪🇸 Sevilla, Spain